Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Challenges in the Measurement and Interpretation of Serum Titanium Concentrations.

Yao JJ, Lewallen EA, Thaler R, Dudakovic A, Wermers M, Day P, Eckdahl S, Jannetto P, Bornhorst JA, Larson AN, Abdel MP, Lewallen DG, van Wijnen AJ.

Biol Trace Elem Res. 2019 Nov 6. doi: 10.1007/s12011-019-01891-4. [Epub ahead of print]

PMID:
31696354
2.

Urinary reference intervals for gadolinium in individuals without recent exposure to gadolinium-based contrast agents.

Bornhorst J, Wegwerth P, Day P, Bryant S, Rokke D, Tervola R, Eckdahl S, Jannetto PJ.

Clin Chem Lab Med. 2019 Oct 17. pii: /j/cclm.ahead-of-print/cclm-2019-0607/cclm-2019-0607.xml. doi: 10.1515/cclm-2019-0607. [Epub ahead of print] No abstract available.

PMID:
31622241
3.

Gadolinium-based contrast agents: A clinically significant analytical interference in inductively coupled plasma mass spectrometry elemental analysis.

Day P, Erdahl S, Eckdahl S, Bornhorst J, Jannetto PJ.

Ann Clin Biochem. 2019 Nov;56(6):638-645. doi: 10.1177/0004563219856031. Epub 2019 Jun 10. No abstract available.

PMID:
31112390
4.

Establishing human heart chromium, cobalt and vanadium concentrations by inductively coupled plasma mass spectrometry.

Day PL, Eckdahl SJ, Maleszewski JJ, Wright TC, Murray DL.

J Trace Elem Med Biol. 2017 May;41:60-65. doi: 10.1016/j.jtemb.2017.02.009. Epub 2017 Feb 16.

PMID:
28347464
5.

Certification of Total Arsenic in Blood and Urine Standard Reference Materials by Radiochemical Neutron Activation Analysis and Inductively Coupled Plasma - Mass Spectrometry.

Paul RL, Davis WC, Yu L, Murphy KE, Guthrie WF, Leber DD, Bryan CE, Vetter TW, Shakirova G, Mitchell G, Kyle DJ, Jarrett JM, Caldwell KL, Jones RL, Eckdahl S, Wermers M, Maras M, Palmer CD, Verostek MF, Geraghty CM, Steuerwald AJ, Parsons PJ.

J Radioanal Nucl Chem. 2014 Mar;299(3):1555-1563.

6.

Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity.

Budihardjo II, Boerner SA, Eckdahl S, Svingen PA, Rios R, Ames MM, Kaufmann SH.

Mol Pharmacol. 2000 Mar;57(3):529-38.

PMID:
10692493
7.

Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.

Bible KC, Boerner SA, Kirkland K, Anderl KL, Bartelt D Jr, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB, Kaufmann SH.

Clin Cancer Res. 2000 Feb;6(2):661-70.

8.

Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent.

Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM.

Biochem Pharmacol. 1999 Sep 15;58(6):1057-66.

PMID:
10509758
9.

6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.

Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH.

Clin Cancer Res. 1998 Jan;4(1):117-30.

10.

Supplemental Content

Loading ...
Support Center